Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 173 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Seroquel Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

NCT04373317
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
24
States / cities
Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

NCT00061802
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
risperidone, quetiapine
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
San Diego, California • Hoffman Est, Illinois • Lake Charles, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 4 Interventional Results available

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

NCT00330863
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

NCT05542264
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Not applicable Interventional Results available

Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder

NCT00617396
View directory record Official record
Conditions
Functional Bowel Disorders
Interventions
Quetiapine (50 mg/day-100mg/day)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 2, 2026, 11:48 AM EDT
Terminated Phase 2 Interventional

A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study

NCT00584688
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
quetiapine
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2012 · Synced Sep 2, 2026, 11:48 AM EDT
Terminated Phase 4 Interventional Results available

Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder

NCT00746421
View directory record Official record
Conditions
Bipolar Disorder, Cognitive Impairment
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder

NCT00156715
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse
Interventions
Quetiapine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Augusta, Georgia • Lebanon, New Hampshire • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 3 Interventional

Phase 3 /Seroquel SR Acute Mania Monotherapy - US

NCT00422123
View directory record Official record
Conditions
Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania, Manic State, Psychoses, Manic-Depressive
Interventions
Quetiapine fumarate (Seroquel) SR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 2, 2026, 11:48 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression

NCT00771134
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lu AA39959, Placebo, Quetiapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 2, 2026, 11:48 AM EDT
Terminated Phase 4 Interventional Results available

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

NCT01844700
View directory record Official record
Conditions
High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
Interventions
Ziprasidone, aripiprazole, quetiapine, or risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
13 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients

NCT00951483
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Quetiapine-XR
Drug
Lead sponsor
Loyola University
Other
Eligibility
20 Years to 65 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

NCT00389064
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
66 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Fort Myers, Florida • Gainsville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders

NCT00326105
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Quetiapine fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
56
States / cities
Phoenix, Arizona • El Centro, California • Irvine, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 3 Interventional

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder

NCT00321490
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Quetiapine fumarate, Duloxetine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 4 Interventional

The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment

NCT00407199
View directory record Official record
Conditions
Social Phobia
Interventions
quetiapine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 25 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 3 Interventional Results available

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

NCT01727726
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
Brexpiprazole, Seroquel XR, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 2, 2026, 11:48 AM EDT
Not listed Phase 4 Interventional

Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

NCT02282085
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Once-Monthly, Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
Drug
Lead sponsor
Matt Byerly
Other
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania

NCT00393978
View directory record Official record
Conditions
Bipolar Disorder, Cannabis-Related Disorder
Interventions
Quetiapine and placebo, Quetiapine and Topiramate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 21 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 2, 2026, 11:48 AM EDT
Completed No phase listed Observational

Functional and Neurochemical Brain Changes in First-episode Bipolar Mania

NCT00609193
View directory record Official record
Conditions
Bipolar Disorder
Interventions
lithium, quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 35 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 4 Interventional

Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults

NCT01224067
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Quetiapine
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 2, 2026, 11:48 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients

NCT00375557
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Behavioral Symptoms
Interventions
Divalproex ER, Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
55 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 4 Interventional

CATIE- Schizophrenia Trial

NCT00014001
View directory record Official record
Conditions
Schizophrenia
Interventions
perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine, fluphenazine decanoate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
54
States / cities
Chula Vista, California • Los Angeles, California • Orange, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Sep 2, 2026, 11:48 AM EDT
Completed Phase 1 Interventional

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

NCT02901587
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lu AF35700 (10 mg/day), Lu AF35700 (30 mg/day), Quetiapine (Seroquel XR® 800 mg/day)
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
21 Years to 60 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 2, 2026, 11:48 AM EDT